ASX - By Stock
|
ATH |
Re:
Ann: New US patent for compounds to treat neurodegeneration
|
|
SunnyKabs
|
9 |
3.6K |
1 |
30/12/22 |
30/12/22 |
ASX - By Stock
|
9
|
3.6K
|
1
|
|
ASX - By Stock
|
ATH |
Re:
New all time low is looming
|
|
SunnyKabs
|
33 |
12K |
0 |
29/12/22 |
29/12/22 |
ASX - By Stock
|
33
|
12K
|
0
|
|
ASX - By Stock
|
ATH |
Re:
Antibiotic Resistance Market worth $18.34 Billion by 2030
|
|
SunnyKabs
|
5 |
2.5K |
0 |
25/12/22 |
25/12/22 |
ASX - By Stock
|
5
|
2.5K
|
0
|
|
ASX - By Stock
|
ATH |
Re:
New all time low is looming
|
|
SunnyKabs
|
33 |
12K |
3 |
25/12/22 |
25/12/22 |
ASX - By Stock
|
33
|
12K
|
3
|
|
ASX - By Stock
|
ATH |
Re:
The shares issued on the 21st of September
|
|
SunnyKabs
|
11 |
4.5K |
0 |
15/10/22 |
15/10/22 |
ASX - By Stock
|
11
|
4.5K
|
0
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Proposed issue of securities - ATH
|
|
SunnyKabs
|
24 |
9.5K |
1 |
21/09/22 |
21/09/22 |
ASX - By Stock
|
24
|
9.5K
|
1
|
|
ASX - By Stock
|
ATH |
Re:
What will be the role of the Fund, if anything
|
|
SunnyKabs
|
5 |
1.8K |
0 |
31/08/22 |
31/08/22 |
ASX - By Stock
|
5
|
1.8K
|
0
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Appendix 4C and Quarterly Cash Flow Report
|
|
SunnyKabs
|
13 |
4.7K |
0 |
30/07/22 |
30/07/22 |
ASX - By Stock
|
13
|
4.7K
|
0
|
|
ASX - By Stock
|
ATH |
Re:
The "AMR" action fund Invested 41M in Adaptive Phage Therapeutics
|
|
SunnyKabs
|
13 |
4.8K |
0 |
24/07/22 |
24/07/22 |
ASX - By Stock
|
13
|
4.8K
|
0
|
|
ASX - By Stock
|
ATH |
Re:
The "AMR" action fund Invested 41M in Adaptive Phage Therapeutics
|
|
SunnyKabs
|
13 |
4.8K |
0 |
24/07/22 |
24/07/22 |
ASX - By Stock
|
13
|
4.8K
|
0
|
|
ASX - By Stock
|
ATH |
Re:
something is going on for pbt2
|
|
SunnyKabs
|
7 |
2.9K |
1 |
21/07/22 |
21/07/22 |
ASX - By Stock
|
7
|
2.9K
|
1
|
|
ASX - By Stock
|
ATH |
Re:
something is going on for pbt2
|
|
SunnyKabs
|
7 |
2.9K |
0 |
19/07/22 |
19/07/22 |
ASX - By Stock
|
7
|
2.9K
|
0
|
|
ASX - By Stock
|
ATH |
Re:
Ann: First Patient dosed in ATH434 Phase 2 Clinical Trial
|
|
SunnyKabs
|
12 |
5.2K |
0 |
09/07/22 |
09/07/22 |
ASX - By Stock
|
12
|
5.2K
|
0
|
|
ASX - By Stock
|
ATH |
Re:
Ann: First Patient dosed in ATH434 Phase 2 Clinical Trial
|
|
SunnyKabs
|
12 |
5.2K |
0 |
07/07/22 |
07/07/22 |
ASX - By Stock
|
12
|
5.2K
|
0
|
|
ASX - By Stock
|
ATH |
Re:
ATH Chart Thread
|
|
SunnyKabs
|
14 |
4.0K |
1 |
06/07/22 |
06/07/22 |
ASX - By Stock
|
14
|
4.0K
|
1
|
|
ASX - By Stock
|
ATH |
Re:
Waiting "tranformative" news
|
|
SunnyKabs
|
8 |
2.8K |
0 |
03/07/22 |
03/07/22 |
ASX - By Stock
|
8
|
2.8K
|
0
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Alterity receives a $4.1 million R&D Tax Refund
|
|
SunnyKabs
|
2 |
1.3K |
0 |
01/07/22 |
01/07/22 |
ASX - By Stock
|
2
|
1.3K
|
0
|
|
ASX - By Stock
|
ATH |
Re:
announcement on PBT2
|
|
SunnyKabs
|
20 |
5.1K |
1 |
27/06/22 |
27/06/22 |
ASX - By Stock
|
20
|
5.1K
|
1
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Alterity to Present at Life Sciences Investor Forum
|
|
SunnyKabs
|
21 |
7.0K |
1 |
25/06/22 |
25/06/22 |
ASX - By Stock
|
21
|
7.0K
|
1
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Alterity to Present at Life Sciences Investor Forum
|
|
SunnyKabs
|
21 |
7.0K |
0 |
23/06/22 |
23/06/22 |
ASX - By Stock
|
21
|
7.0K
|
0
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Alterity to Present at Life Sciences Investor Forum
|
|
SunnyKabs
|
21 |
7.0K |
1 |
22/06/22 |
22/06/22 |
ASX - By Stock
|
21
|
7.0K
|
1
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Meeting with US FDA provides development path for ATH434
|
|
SunnyKabs
|
13 |
8.0K |
2 |
17/06/22 |
17/06/22 |
ASX - By Stock
|
13
|
8.0K
|
2
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Alterity to present at GCFF Virtual Conference 2022
|
|
SunnyKabs
|
11 |
4.2K |
0 |
15/06/22 |
15/06/22 |
ASX - By Stock
|
11
|
4.2K
|
0
|
|
ASX - By Stock
|
ATH |
Re:
Old news about otitis study
|
|
SunnyKabs
|
2 |
999 |
0 |
08/06/22 |
08/06/22 |
ASX - By Stock
|
2
|
999
|
0
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Alterity Launches ATH434 Phase 2 Clinical Trial
|
|
SunnyKabs
|
12 |
5.2K |
0 |
02/06/22 |
02/06/22 |
ASX - By Stock
|
12
|
5.2K
|
0
|
|
ASX - By Stock
|
ATH |
Re:
New Zealand Brain Research Institute recruiting for phase 2
|
|
SunnyKabs
|
5 |
1.9K |
1 |
26/05/22 |
26/05/22 |
ASX - By Stock
|
5
|
1.9K
|
1
|
|
ASX - By Stock
|
ATH |
Re:
What's Happening Regarding Regaining Nasdaq Compliance?
|
|
SunnyKabs
|
8 |
2.5K |
3 |
26/05/22 |
26/05/22 |
ASX - By Stock
|
8
|
2.5K
|
3
|
|
ASX - By Stock
|
ATH |
Re:
What is happening with PBT2?
|
|
SunnyKabs
|
25 |
10K |
0 |
24/05/22 |
24/05/22 |
ASX - By Stock
|
25
|
10K
|
0
|
|
ASX - By Stock
|
ATH |
Re:
What is happening with PBT2?
|
|
SunnyKabs
|
25 |
10K |
2 |
12/05/22 |
12/05/22 |
ASX - By Stock
|
25
|
10K
|
2
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Appendix 4C and Quarterly Cash Flow Report
|
|
SunnyKabs
|
11 |
4.4K |
1 |
05/05/22 |
05/05/22 |
ASX - By Stock
|
11
|
4.4K
|
1
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Appendix 4C and Quarterly Cash Flow Report
|
|
SunnyKabs
|
11 |
4.4K |
0 |
04/05/22 |
04/05/22 |
ASX - By Stock
|
11
|
4.4K
|
0
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Appendix 4C and Quarterly Cash Flow Report
|
|
SunnyKabs
|
11 |
4.4K |
0 |
03/05/22 |
03/05/22 |
ASX - By Stock
|
11
|
4.4K
|
0
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Appendix 4C and Quarterly Cash Flow Report
|
|
SunnyKabs
|
11 |
4.4K |
0 |
01/05/22 |
01/05/22 |
ASX - By Stock
|
11
|
4.4K
|
0
|
|
ASX - By Stock
|
ATH |
Re:
Ann: UK Regulatory Authorisation to Proceed with Phase 2 Trial
|
|
SunnyKabs
|
17 |
5.9K |
1 |
27/04/22 |
27/04/22 |
ASX - By Stock
|
17
|
5.9K
|
1
|
|
ASX - By Stock
|
ATH |
Doomed to Fail
|
|
SunnyKabs
|
2 |
987 |
0 |
22/04/22 |
22/04/22 |
ASX - By Stock
|
2
|
987
|
0
|
|
ASX - By Stock
|
ATH |
Re:
2nd quarter update
|
|
SunnyKabs
|
2 |
998 |
0 |
20/04/22 |
20/04/22 |
ASX - By Stock
|
2
|
998
|
0
|
|
ASX - By Stock
|
ATH |
2nd quarter update
|
|
SunnyKabs
|
2 |
998 |
0 |
20/04/22 |
20/04/22 |
ASX - By Stock
|
2
|
998
|
0
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Presentation of bioMUSE Data at the AAN Annual Meeting
|
|
SunnyKabs
|
10 |
3.5K |
2 |
07/04/22 |
07/04/22 |
ASX - By Stock
|
10
|
3.5K
|
2
|
|
ASX - By Stock
|
ATH |
Struggling to get back into compliance
|
|
SunnyKabs
|
1 |
639 |
2 |
06/04/22 |
06/04/22 |
ASX - By Stock
|
1
|
639
|
2
|
|
ASX - By Stock
|
ATH |
Re:
The first investment of the Action Fund was announced
|
|
SunnyKabs
|
9 |
2.7K |
1 |
06/04/22 |
06/04/22 |
ASX - By Stock
|
9
|
2.7K
|
1
|
|
ASX - By Stock
|
ATH |
Re:
Shorts on low level
|
|
SunnyKabs
|
18 |
5.2K |
0 |
31/03/22 |
31/03/22 |
ASX - By Stock
|
18
|
5.2K
|
0
|
|
ASX - By Stock
|
ATH |
PBT2 Chatter for Life Bio
|
|
SunnyKabs
|
3 |
1.1K |
0 |
24/03/22 |
24/03/22 |
ASX - By Stock
|
3
|
1.1K
|
0
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Change in substantial holding
|
|
SunnyKabs
|
4 |
1.6K |
0 |
22/03/22 |
22/03/22 |
ASX - By Stock
|
4
|
1.6K
|
0
|
|
ASX - By Stock
|
ATH |
Re:
Duchenne muscle dystrophy / iron chelation
|
|
SunnyKabs
|
2 |
1.1K |
0 |
16/03/22 |
16/03/22 |
ASX - By Stock
|
2
|
1.1K
|
0
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Alterity to participate in Sachs Neuroscience Conference
|
|
SunnyKabs
|
3 |
1.3K |
1 |
16/03/22 |
16/03/22 |
ASX - By Stock
|
3
|
1.3K
|
1
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Investor Presentation
|
|
SunnyKabs
|
8 |
3.6K |
0 |
08/03/22 |
08/03/22 |
ASX - By Stock
|
8
|
3.6K
|
0
|
|
ASX - By Stock
|
ATH |
Re:
Volumes are down
|
|
SunnyKabs
|
10 |
4.3K |
0 |
03/03/22 |
03/03/22 |
ASX - By Stock
|
10
|
4.3K
|
0
|
|
ASX - By Stock
|
ATH |
Re:
Ann: NASDAQ Non-Compliance Notice Received
|
|
SunnyKabs
|
3 |
1.7K |
0 |
01/03/22 |
01/03/22 |
ASX - By Stock
|
3
|
1.7K
|
0
|
|
ASX - By Stock
|
ATH |
Re:
PBT2 for Middle Ear Infections
|
|
SunnyKabs
|
28 |
6.4K |
0 |
25/02/22 |
25/02/22 |
ASX - By Stock
|
28
|
6.4K
|
0
|
|
ASX - By Stock
|
ATH |
Re:
AMR Action Fund Opens European Office
|
|
SunnyKabs
|
8 |
2.3K |
1 |
22/02/22 |
22/02/22 |
ASX - By Stock
|
8
|
2.3K
|
1
|
|